Introduction
Gliomas are the most common tumors of the central nervous system (CNS) derived from glial cells and classified into four clinical grades (World Health Organization (WHO) grades I-IV; Kleihues et al., 1995; Dai and Holland, 2001) . Glioblastoma multiforme (GBM; WHO grade IV) is the most malignant type with a mean survival time of approximately 9-12 months (Vajkoczy and Menger, 2000) . Common features of GBMs include fast cell proliferation, invasion into normal brain parenchyma, intratumoral necrosis, hypoxia and high angiogenic activity (Vajkoczy et al., 1999; Louis, 2006) .
The microenvironment of the CNS is maintained by the blood-brain barrier (BBB) formed by specialized endothelial cells, which are distinguished from those in the periphery by high mitochondrial content (Oldendorf et al., 1977) , lack of fenestrations, minimal pinocytic activity and the presence of tight junctions that restrict paracellular permeability of hydrophilic molecules (Kniesel and Wolburg, 2000) . GBM vessels lose many BBB properties, leading to clinical signs of brain edema due to increased vessel permeability (Long, 1970) . Morphologically, GBM vessels are characterized by fenestrations, increased number of caveolae, wide intercellular junctions, abnormal pericytes and a discontinuous basement membrane (Hirano and Matsui, 1975; Dinda et al., 1993) . GBM vessels express unique gene and protein biomarkers (Pen et al., 2007) , often associated with angiogenesis and/or increased permeability, including aquaporin 4 (Davies, 2002) , plasmalemmal vesicle associated protein-1 (Madden et al., 2004) and TEM7 (PLXDC1; Beaty et al., 2007) . Recent transcriptomic analysis of laser-captured microdissected vessels from GBM tumors identified insulin-like growth factor-binding protein 7 (IGFBP7) as a highly selective biomarker of tumor vessels (Pen et al., 2007) . IGFBP7 was expressed by GBM endothelial cells and extensively deposited into the vascular basal lamina (Pen et al., 2007) .
IGFBP7 is a related member of the IGFBP family , cloned by several groups (Murphy et al., 1993; Akaogi et al., 1994; Yamauchi et al., 1994) , which, unlike the other family members (IGFBP1-6), exhibits a low affinity for IGF but a high and specific affinity for insulin (Oh et al., 1996) . IGFBP7 is a cell adhesive glycoprotein of about 30 kDa (Akaogi et al., 1994) , which is regulated by proteolytic cleavage into a two-chain form by a membrane-bound serine proteinase matriptase (Ahmed et al., 2006) . Varied IGFBP7 expression patterns have been reported in different tumor types . IGFBP7 transcription in tumor cells is modulated by DNA methylation (Komatsu et al., 2000) , retinoic acid and transforming growth factor (TGF)-b1 . IGFBP7 has been implicated in tumor growth suppression (Burger et al., 1998; Sprenger et al., 1999 ) through induction of apoptosis or cellular senescence (Wilson et al., 2002; Mutaguchi et al., 2003) . Recently, Wajapeyee et al. (2008) identified a mechanism by which BRAF protooncogene triggers cellular senescence in melanocytes through induction of IGFBP7.
In contrast to the tumor suppressor role of IGFBP7 in cancer cells, IGFBP7 is highly upregulated in vessels of several tumors, including GBM (Akaogi et al., 1996; Pen et al., 2007) , and interacts in vitro with various extracellular matrix (ECM) proteins to stimulate adhesion and migration/invasion of vascular endothelial cells on plastic substrates (Sato et al., 1999; Kishibe et al., 2000) ; hence, the original name 'angiomodulin' (Akaogi et al., 1996) . Although literature evidence suggests that IGFBP7 might exhibit angiogenesis-modulating properties (Akaogi et al., 1996; van Beijnum et al., 2006) , the role of IGFBP7 in tumor angiogenesis remains poorly understood.
As IGFBP7 is selectively expressed in GBM vessels, the goal of this study was to identify the components of the glial tumor microenvironment that induce IGFBP7 expression in brain endothelial cells and to determine the potential role of IGFBP7 in angiogenesis. IGFBP7 expression in brain endothelial cells was found to be unresponsive to hypoxia, but upregulated by secreted factors from GBM cells through TGF-b1/ALK5/Smad-2 signaling pathway.
Results

Glioblastoma-conditioned media induces IGFBP7 in human brain endothelial cells
To examine whether tumor-like microenvironment affects the expression of IGFBP7 in brain endothelial cells, cultured human brain endothelial cells (HBECs) were exposed to either hypoxia (Vaupel et al., 1998) or media conditioned by the human GBM cell line, U87MG (U87MG-CM). Under control conditions, HBEC exhibited low abundance of IGFBP7 transcripts (two to threefold lower than b-actin in the same cells) (Figure 1a , upper panel) and protein (Figure 1a, lower panel, c, d) , in agreement with the observed absence of IGFBP7 protein immunoreactivity in nonmalignant brain vessels in vivo (Pen et al., 2007) . Whereas hypoxia failed to induce IGFBP7 (A Pen, unpublished), HBEC exposed to U87MG-CM responded with a time-dependent upregulation of IGFBP7 mRNA ( Figure 1a , upper panel) and IGFBP7 protein ( Figure 1a , lower panel), reaching maximal levels after 3-6 days of incubation in U87MG-CM. The pronounced upregulation of IGFBP7 protein at 6 days of exposure to U87MG-CM was detected by western blot in both HBEC lysates ( Figure 1c ) and in the secreted fractions (Figure 1a, lower panel, d) . Conditioned media (CM) from another human GBM cell line, T98G, induced IGFBP7 mRNA and protein in HBEC in a similar fashion as that observed with U87MG-CM (Supplementary Figure S1) . IGFBP7 protein was not detected in either U87MG-CM (Figure 1d ) or T98G-CM (Supplementary Figure S1 , lower panel).
Heat-inactivated U87MG-CM lost the ability to induce IGFBP7 mRNA ( Figure 1b ) and protein ( Figures 1c and d ) expression in HBEC, suggesting that heat-liable mediator(s), most likely proteins, produced by GBM cells were responsible for IGFBP7 induction.
IGFBP7 gene methylation in HBEC is not affected by glioblastoma-conditioned media To investigate whether IGFBP7 induction in HBEC treated with U87MG-CM was the result of DNA demethylation, the methylation status of IGFBP7 gene in HBEC treated with either Dulbecco's modified Eagle's medium (DMEM; control) or U87MG-CM was analysed (as described in Supplementary Materials and Methods; Miller et al., 1998; Deb-Rinker et al., 2005) using primer sets (Supplementary Table 1 ) designed to amplify cytosine-phosphate-guanine (CpG) sites present in the promoter region (primer sets A and B) or exon 1 and exon 1/intron 1 (primer sets C and D, respectively) of IGFBP7 gene (Chen et al., 2007) . The methylation status of DMEM-and U87MG-CM-treated HBEC in the exon 1 region ( þ 73 to þ 472; primer pair IGFBP7-C) of IGFBP7 spanning 45 CpG sites could not be determined, possibly due to the high density of CpG islands present in this region resulting in unspecific PCR products. The PCR-amplified fragment spanning 19 CpG sites ( þ 464 to þ 649; primer pair IGFBP7-D) showed a higher (but not statistically significant) number of methylation sites in control HBEC DNA compared to U87MG-CM-treated HBEC DNA (Supplementary Figure S2, graph) . No differences in methylation state were detected within the 5 CpG (À941 to À766; primer pair IGFBP7-A) and 6 CpG (À789 to À577; primer pair IGFBP7-B) sites of IGFBP7 promoter regions (Supplementary Figure S2 ). As no specific CpG sites were consistently and significantly methylated in control and demethylated in U87MG-CM-treated HBEC, we concluded that IGFBP7 induction in U87MG-CM exposed HBEC was most likely regulated by mechanisms other than IGFBP7 DNA methylation.
TGF-b1 induces IGFBP7 expression in HBEC
The nature of IGFBP7-inducing mediators present in U87MG-CM was examined next. From our previous studies (Moreno et al., 2006) analysing U87MG cell Tumor cells induce IGFBP7 in endothelium A Pen et al transcriptome, we selected and examined two secreted angiogenic proteins identified by enzyme-linked immunosorbent assay (ELISA) in U87MG-CM, VEGF-A and SPARC, for their ability to induce IGFBP7 expression in HBEC. Either VEGF-A or SPARC (20 ng/ml) demonstrated minimal effects on IGFBP7 expression in HBEC (A Pen, unpublished) . On the basis of previous studies showing that TGF-b1 induces IGFBP7 expression in bovine retinal capillary endothelial cells (Hata et al., 2000) , we examined whether TGFb1 is released in U87MG-CM. The average amount of TGF-b1 secreted in U87MG-CM determined by ELISA was B5 pM. HBEC exposed to 5 pM TGF-b1 responded with a time-dependent upregulation of IGFBP7 mRNA (Figure 2a, upper panel) and protein ( Figure 2a , lower panel), reaching maximal levels 3-6 days after IGFBP7 addition. In HBEC exposed to TGF-b1 concentrations ranging from 5 to 100 pM for 6 days, IGFBP7 mRNA was upregulated in a dose-dependent manner, with EC 50 ¼ 12 pM (Figure 2b ). The IGFBP7 induction with 5 pM TGF-b1 was similar (2.5-to 4-fold) to that observed with U87MG-CM (Figures 1 and 2) .
To confirm that secreted TGF-b1 is responsible for the IGFBP7 upregulation, U87MG-CM were pretreated Figure S3) . However, only TGF-b2 isoform was detected in U87MG-CM by ELISA (B2-5 pM) suggesting that TGF-b2, in addition to TGF-b1, may participate in U87MG-CM-mediated induction of IGFBP7 expression in HBEC.
TGF-b1 modulates IGFBP7 expression through ALK5 receptor and the signal transduction adapter proteins Smad-2 and Smad-1/-5 TGF-b1 has been reported to regulate angiogenesis in endothelial cells through two Smad pathways: the canonical Smad-2/-3/-4 pathway by its predominant type I receptor activin receptor-like kinase (ALK) 5, and the Smad-1/-5/-4 pathway by ALK1 (Lebrin et al., 2005) . To investigate which signaling cascade triggers TGF-b1-mediated induction of IGFBP7, HBEC were exposed to TGF-b1 or U87MG-CM in the presence of SB431542, a selective antagonist of ALK5, but not of ALK1 (Inman et al., 2002) . Both IGFBP7 mRNA ( Figure 3a ) and protein induction and release ( Figure 3b ) stimulated by TGF-b1 or U87MG-CM were completely inhibited in the presence of 10 mM SB431542 (Figures 3a and b) . The levels of phosphorylated Smad-2 and Smad-1/-5 were examined in nuclear (c) IGFBP7 mRNA expression in HBEC exposed to 5 pM TGF-b1 or U87MG-CM in the absence or presence of 1.25 mg/ml of the pan-TGF-b-neutralizing antibody 1D11 (R&D System). (d) IGFBP7 mRNA expression in HBEC exposed to 5 pM TGF-b1 or U87MG-CM in the absence or presence of 20 or 200 ng/ml of TGF-b1-specific neutralizing antibody (R&D System). Relative expression of IGFBP7 mRNA was normalized to that of b-actin in same cell extracts. Each bar represents the mean ± s.e.m. of at least three experiments. Asterisks indicate significance between DMEM-treated and TGF-b1-or U87MG-CM-treated HBEC; # and þ þ indicate significance between 5 pM TGF-b1-or U87MG-CM-treated HBEC, respectively, in the absence or presence of the neutralizing antibodies. Significance (Po0.001) was determined by analysis of variance (ANOVA) followed by Newman-Keuls posttest comparison among means.
Tumor cells induce IGFBP7 in endothelium A Pen et al and cytosolic extracts of cells treated with TGF-b1 or U87MG-CM in the absence or presence of SB431542; whereas the levels of Smad-2 and Smad-5 in the cytosolic extracts remained unchanged in differently treated cells (Figure 4 , lower panel), a strong Smad-2 phosphorylation and a weaker Smad-1/-5 phosphorylation in response to both TGF-b1 and U87MG-CM was observed in the nuclear extracts of HBEC (Figure 4 , upper panel). TGF-b1 was previously shown to induce both Smad-2 and Smad-1/-5 phosphorylation in wildtype mouse embryonic endothelial cells and bovine aortic endothelial cells (Goumans et al., 2002) . Both TGF-b1-and U87MG-CM-induced Smad-2 and Smad-1/-5 phosphorylation were inhibited in the presence of SB431542. As SB431542 has no effect on ALK1/Smad phosphorylation (Goumans et al., 2003; Watabe et al., 2003) , these observations suggest that ALK1-mediated phosphorylation of Smad-1/-5 in HBEC cells is probably induced secondary to the activation of ALK5. Findings by Goumans et al. (2003) demonstrating that ALK5 kinase activity is required for ALK1 activation by TGF-b support this conclusion. These results suggest that U87MG-CM induces IGFBP7 in HBEC preferentially through ALK5 pathway leading to Smad-2 protein phosphorylation.
IGFBP7-induced capillary formation
To evaluate the effect of IGFBP7 protein on endothelial cells, a recombinant IGFBP7 was produced and purified (as described in Supplementary Materials and Methods; Durocher et al., 2002) . Recombinant IGFBP7 was detected by SDS-polyacrylamide gel electrophoresis (PAGE) Coomassie blue staining (Supplementary Figure S4A) and by western blot using a penta-His horseradish peroxidase (HRP) antibody (Supplementary Figure S4B) as a band of approximately 37 kDa. Mass spectrometry analysis indicated that IGFBP7 purity was B90-95% and that the contaminant band observed at B200 kDa in SDS-PAGE gel was collagen II a-precursor (A Pen, unpublished). IGFBP7 functionality/activity was determined by its ability to bind rh6Ckine/CCL21 (Nagakubo et al., 2003; Supplementary Figure S4C) . Transforming growth factor (TGF)-b1 induces insulinlike growth factor-binding protein 7 (IGFBP7) through ALK5/ Smad-2 pathway. Human brain endothelial cells (HBECs) were treated with DMEM, 5 pM TGF-b1 or U87MG-CM alone or in the presence of 10 mM of the ALK5 antagonist SB431542 for 30 min at 37 1C before lysis. SB431542 was added to HBEC 20 min before TGF-b1 or U87MG-CM. Nuclear and cytosolic extracts were isolated as described in 'Materials and methods' section. The phosphorylation of Smad-2 and Smad-1/-5 was analysed by western blot using respective anti-phospho-Smad antibodies. Cytosolic fraction was probed by respective anti-Smad antibodies. NuMA and actin were used as controls for nuclear and cytosolic protein loading, respectively. Gels shown are representative of three separate experiments showing similar results.
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To assess whether IGFBP7 has angiogenic activity, HBECs grown in Matrigel, a biological basement membrane matrix, were exposed to DMEM or U87MG-CM or to different concentrations of IGFBP7. HBEC exposed to U87MG-CM for 24 h (Figure 5c ) formed an extensive network of capillary-like tubes (CLTs) compared to cells cultured in DMEM alone (Figure 5a ), quantified as significant increases in both total length of capillary cords and the number of branching nodes (Figure 5d ). IGFBP7 also induced CLT formation in HBEC (Figure 5b ) with a maximal induction observed at 50 nM (Figure 5d ), suggesting a proangiogenic activity of IGFBP7 in the examined concentration range.
To examine if the proangiogenic activity of U87MG-CM is associated with TGF-b signaling pathway, HBEC were exposed to U87MG-CM in the presence of 10 mM SB431542. U87MG-CM-induced CLT formation in HBEC (Figures 6a and b) was reduced to control levels in the presence of 10 mM SB431542 (Figures 6c and d) . The same concentration of SB431542 solvent, DMSO, did not affect CLT formation (A Pen, unpublished) . These results imply that TGF-b signaling through ALK5 is necessary for the proangiogenic activity of U87MG-CM. # indicates significance between U87MG-CM in the absence or presence of 10 mM SB431542. Significance (Po0.05) was determined by analysis of variance (ANOVA) followed by Newman-Keuls posttest comparison among means.
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Discussion
The selective upregulation of IGFBP7 in GBM vessels compared to nonmalignant brain vessels (Pen et al., 2007) suggests a role for IGFBP7 in tumor vascular function. However, the mechanisms of IGFBP7 induction and its role in tumor angiogenesis are poorly understood. The present study provides the first evidence that IGFBP7 is induced in HBEC by GBM-cell-secreted mediators, including TGF-b1, through TGF-b1/ALK5/ Smad-2 pathway and by a DNA methylation-independent mechanism. Furthermore, IGFBP7 is shown to stimulate HBEC angiogenic phenotype and may be involved in angiogenesis induced by tumor microenvironment.
IGFBP7 stimulation by tumor microenvironment in brain endothelial cells was investigated by probing both potential mechanisms of IGFBP7 gene regulation in endothelial cells and the nature and signaling pathways induced by secreted mediators (proteins in CM) of GBM cells.
Compelling literature evidence indicates that hypermethylation of CpG islands of IGFBP7 is responsible for downregulation of IGFBP7 in tumor cells contributing to tumor progression (Komatsu et al., 2000; Chen et al., 2007; Lin et al., 2007) . In contrast to colon (Lin et al., 2007) and lung (Chen et al., 2007) IGFBP7-negative cancer cell lines in which sites þ 490 to þ 610 of the 5 0 CpG island of IGFBP7 gene were all methylated, neither these sites ( þ 490 to þ 610) nor promoter regions of IGFBP7 were highly methylated in either control or U87MG-CM-treated HBEC. These results suggest that IGFBP7 gene regulation by DNA methylation is likely different between cancer cells and endothelial cells, and that DNA demethylation was not involved in regulating IGFBP7 gene induction in HBEC.
IGFBP7 expression in peripheral endothelial cells can be modulated by cell confluence, hypoxia, and cytokines including VEGF, bFGF and TGF-b1 (Hata et al., 2000) . In this study, IGFBP7 expression in HBEC was potently induced by U87MG-CM and TGF-b1 and was not affected by VEGF or hypoxia. TGF-b is a 25 kDa homodimeric protein present in three isoforms: TGF-b1, -b2 and -b3 (Lebrin et al., 2005) ; the three isoforms of TGFb interact with the same cell surface serine/threonine kinase receptor type I (TbR-I) and type II (TbR-II) (ten Dijke et al., 1988; de Caestecker, 2004) to induce several common but also distinct responses (Lebrin et al., 2005) . GBM tumors express all three TGF-b isoforms (Constam et al., 1992; Olofsson et al., 1992; Weller et al., 1995; Yamada et al., 1995; Wick et al., 2001) . Although all three TGF-b isoforms can induce IGFBP7 expression in HBEC, only TGF-b1 and -b2 were detected in U87MG-CM. As the specific TGF-b1-neutralizing antibody only partially blocked U87MG-CM-induced IGFBP7 expression, in contrast to the complete inhibition observed with the pan-TGF-bs antibody (1D11), it is suggested that TGF-b1 and -b2 isoforms are key U87MG-released mediators that stimulate IGFBP7 in HBEC.
TGF-b has been implicated in various biological functions including cell cycle control, carcinogenesis, invasion, metastasis (Massague, 1998) and vascular remodeling (Pepper, 1997) , acting as either an inhibitor or stimulator of angiogenesis depending on experimental conditions (Goumans et al., 2002) . TGF-b signaling is initiated by binding of the ligand to its constitutively active cell surface receptor, TbR-II. Upon binding, TbR-II activates and phosphorylates TbR-I, also known as ALK (de Caestecker, 2004) . Subsequently, the signal is propagated to the nucleus by phosphorylated Smad proteins where they participate in transcriptional regulation of target genes (Derynck et al., 1998) . Although activated ALK5 induces phosphorylation of Smad-2/-3, ALK1 induces the phosphorylation of Smad-1/-5 (Chen and Massague, 1999) . Preferential induction of ALK1 or ALK5 signaling activity (Goumans et al., 2002) is dependent on TGF-b concentrations: Smad-2 phosphorylation is initiated at 1 pM and is maximal at 10 pM TGF-b, whereas Smad-5 phosphorylation is triggered by 10-20 pM of TGF-b (Goumans et al., 2002) . We propose that TGF-bs (-1 and -2) secreted by GBM cells mediate IGFBP7 induction in HBEC by preferentially activating ALK5/ Smad-2 signaling pathway based on the following observations: (1) measured levels of TGF-b1 in U87MG-CM were B5 pM, (2) the U87MG-CM induction of IGFBP7 was completely blocked by a selective inhibitor of ALK5, SB431542 and (3) increases in phosho-Smad-2 detected in nuclear extracts of HBEC in response to both TGF-b1 and U87MG-CM were also inhibited by SB431542. The observed weak increases in phosphorylated Smad-1/-5 after TGF-b1 or U87MG-CM addition indicate that IGFBP7 expression can also be induced by activation of ALK1/Smad-1/-5 pathway. However, as SB431542 partially blocked these responses, the phosphorylation of Smad-1/-5 appears to be in part secondary to the activation of ALK5. TGF-b1 can also act through receptor-dependent, but Smadindependent pathways, including the activation of mitogen-activated protein kinase (Blanchette et al., 2001) , c-Jun N-terminal kinase (Engel et al., 1999) and protein kinase C (Yakymovych et al., 2001) .
In this study, the IGFBP7 induction was observed as early as 24 h after HBEC treatment with either TGF-b1 or U87MG-CM, reaching maximal levels of mRNA and/or protein upregulation after 6 days. Given this prolonged time course, autocrine stimulation by other TGF-b1-induced mediators might in part be responsible for IGFBP7 induction.
The study further provides evidence of proangiogenic function of IGFBP7 in HBEC. Whereas IGFBP7 failed to stimulate HBEC proliferation (A Pen, unpublished), it induced a dose-dependent elaboration of CLT networks in HBEC grown in Matrigel. In agreement with this observation, a recent study demonstrated that IGFBP7 antibody inhibits endothelial tube formation in an in vitro collagen gel-based sprout formation assay (van Beijnum et al., 2006) . HBEC CLT formation induced by U87MG-CM was inhibited by the ALK5 antagonist, SB431542, implicating TGF-b/ALK5 signaling pathway in U87MG-CM-induced angiogenic responses. As the same pathway was responsible for Tumor cells induce IGFBP7 in endothelium A Pen et al IGFBP7 induction in HBEC, it is tempting to speculate that autocrine actions of IGFBP7 could participate in U87MG-CM-induced angiogenic responses in HBEC. TGF-b mediates the transcription of several genes related to the ECM remodeling, including SPARC and collagen I (Reed et al., 1994) , MMP-2, TIMP-1 (Kwak et al., 2006) , plasminogen activator inhibitor-1 (Keeton et al., 1991) and collagen IV (Poncelet and Schnaper, 1998) . Secreted IGFBP7 is known to interact with ECM components (Akaogi et al., 1996; St Croix et al., 2000) , and could thus participate in the TGF-b1-induced ECM turnover and angiogenesis. Whereas inhibition of CLT formation was observed by TGF-b1 alone, in combination with VEGF and angiopoietin 1, CLT formation is rescued and stabilized, suggesting that the process is regulated by the interaction of angiogenic and antiangiogenic growth factors (Ramsauer and D'Amore, 2007) . The process of angiogenesis is characterized by two different phases (Lebrin et al., 2005) : an activation phase accompanied by increased vascular permeability, degradation of the basement membrane, endothelial cell proliferation and migration, and the late phase typified by the inhibition of endothelial cell proliferation and migration, reforming of the basement membrane and stabilization and maturation of the vessel. A recent model proposed that the activation phase of angiogenesis is promoted by TGF-b1/ALK1/Smad-1/-5 signaling pathway, whereas the late phase is induced by TGF-b1/ ALK5/Smad-2/-3 pathway (Goumans et al., 2002) ; given that both Smad-2 and Smad-1/-5 can be activated by TGF-b in endothelial cells, the overall angiogenesis outcome is likely dependent on the balance between TGF-b-induced ALK1 or ALK5 activation (Goumans et al., 2002) . As (1) endothelial IGFBP7 induction by tumor microenvironment is predominantly mediated by ALK5/Smad-2 pathway, (2) IGFBP7 accumulates in the basal lamina of GBM vessels in vivo (Pen et al., 2007) and (3) IGFBP7 does not stimulate endothelial cell proliferation, we propose that IGFBP7 might be involved in the late phase of angiogenesis in the context of GBM tumors. Proposed mechanisms of GBM-and TGF-b-mediated induction of IGFBP7 in HBEC are shown schematically in Figure 7 .
The proposed angiogenic role of IGFBP7 may appear contradictory to literature evidence of tumor-suppresor actions of IGFBP7 (Sprenger et al., 1999; Wilson et al., 2002; Mutaguchi et al., 2003; Wajapeyee et al., 2008) . The first line of explanation is that IGFBP7 could trigger differential signaling pathways in tumor and endothelial cells; for example, in melanocytes, BRAF oncogene induces IGFBP7 that causes cellular senescence through inhibition of BRAF-MEK-ERK signaling (Wajapeyee et al., 2008) , whereas in endothelial cells IGFBP7 is induced through TGF-b/ALK5/Smad-2 and participates in late-stage angiogenesis. As there is currently no clear understanding whether late-stage angiogenesis contributes to tumor progression or tumor growth stabilization, the overall effect of IGFBP7 in tumor milieu cannot be easily generalized. Further understanding of the regulation and functions of this highly selective biomarker of tumor vessels will be important in developing appropriate therapies for GBM tumors as well as other tumors characterized by high vascular expression of IGFBP7 such as colon cancer (Umeda et al., 1998; van Beijnum et al., 2006) .
Materials and methods
Reagents and antibodies TGF-b1 recombinant protein, TGF-b1 polyclonal antibody (AF-101-NA) and pan-TGF-b-neutralizing monoclonal antibody (1D11) were purchased from R&D System (Minneapolis, MN, USA). The TGF-b type I receptor (ALK5) inhibitor, SB431542 was purchased from Sigma (St Louis, MO, USA). Primary antibodies for western blot included mouse monoclonal antibodies to Smad-2 (BD Biosciences, Bedford, MA, USA) and to actin (Chemicon, Temecula, CA, USA), polyclonal antibody to P-Smad-2, P-Smad-1/-5 and Smad-5 (Cell Signaling, Beverly, MA, USA) and polyclonal antibody to IGFBP7 (R&D System).
Cell cultures
HBECs were obtained from small intracortical microvessels (20-112 mm) harvested from temporal cortex from patients treated surgically for idiopathic epilepsy as previously Figure 7 Proposed mechanism of U87MG-CM and transforming growth factor (TGF)-b-mediated insulin-like growth factor-binding protein 7 (IGFBP7) induction in human brain endothelial cell (HBEC). U87MG-CM secretes several factors including TGF-bs. TGF-bs bind to TGF-b type II receptor (TbR-II) at the surface of endothelial cells, which in turn recruits TGF-b type I receptor (TbR-I) ALK1 or ALK5. Activated TbR-II and TbR-I complexes stimulate both Smad-1/-5 and Smad-2/-3 phosphorylation; IGFBP7 transcription in this system appears to be preferentially induced by Smad-2/-3 complexing with Smad-4 (bold arrows). ALK1-mediated phosphorylation of Smad-1/-5 could be secondary to the activation of ALK5 (dash arrows). IGFBP7, in concert with other TGF-b-induced genes/proteins, participates in promoting late-phase angiogenesis.
Tumor cells induce IGFBP7 in endothelium A Pen et al described (Stanimirovic et al., 1996) . Tissues were obtained with approval from the Office of Research Ethics Boards. HBEC were grown at 37 1C in media containing Earle's salts, 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 4.35 g/l sodium bicarbonate, and 3 mM L-glutamine, 10% fetal bovine serum (FBS), 5% human serum, 20% of media conditioned by murine melanoma cells, 5 mg/ml insulin, 5 mg/ml transferrin, 5 ng/ml selenium and 10 mg/ml endothelial cell growth supplement. HBEC cultures were routinely characterized for purity and the expression of endothelial cell markers (Stanimirovic et al., 1996) . Passages 4-6 were used in this study.
The human glioma cell lines U87MG and T98G were established from surgically removed type III glioma/GBM and GBM, respectively, and were both obtained from the American Type Culture Collection. U87MG cells were grown at 37 1C in DMEM supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, 0.25 mg/ml amphotericin B with 0.085 g/l NaCl and 10% heat-inactivated FBS (HyClone, Logan, UT, USA) in humidified atmosphere of 5% CO 2 / 95% air. T98G cells were cultured in minimum essential medium Eagle (MEM; Sigma) supplemented with 10% FBS. Media for both cell lines were changed every 2-3 days.
Preparation of U87MG-and T98G-conditioned media U87MG cells and T98G cells (5 Â 10 4 cells per ml) were plated in poly-L-lysine (25 mg/ml) precoated and noncoated 75 cm 2 Falcon tissue culture flasks, respectively (Becton Dickinson Labware, Franklin Lakes, NJ, USA), and incubated at 37 1C in growth medium. U87MG and T98G growth media were replaced with serum-free DMEM and MEM, respectively, 4 days after plating. Serum-free media were collected after 3 days and filtered (Millex-GV sterilizing filter membrane, 0.22 mm).
ELISA
The levels of secreted human TGF-b1, TGF-b2 and TGF-b3 in serum-free CM from U87MG cells were determined using DuoSet ELISA Development System kits (R&D System) according to manufacturer's protocol.
Cell treatments HBEC grown in 35 mm dishes were washed with DMEM and growth medium was replaced by DMEM alone or supplemented with different concentration of TGF-b1 recombinant protein, U87MG-CM either inactivated by boiling at 95 1C for 10 min or fresh, in the absence or presence of a pan-TGF-bneutralizing antibody (1D11), an ALK5 inhibitor (SB431542) or a TGF-b1 polyclonal antibody for various periods of time. The treatments were refreshed at day 3. The expression of IGFBP7 was evaluated by real-time Q-PCR and western blot analyses.
Quantitative real-time Q-PCR Total RNA from either untreated or treated HBEC was extracted using TRIzol Reagent (Gibco BRL, Gaithersburg, MD, USA) and reverse-transcribed into cDNA using Superscript II reverse transcriptase (Invitrogen, Burlington, ON, Canada). Quantitative Q-PCR reactions were performed with iTaq SYBR Green Supermix (Bio-Rad, Mississauga, Ontario, Canada) using an ABI Prism 7700 Sequence Detector System (Applied Biosystems, Foster City, CA, USA). Primers used for real-time Q-PCR were designed according to sequences in GenBank (Table 1 ). The thermal PCR conditions were 15 s denaturation at 95 1C and 1 min annealing extension at 60 1C for 40 cycles. Fluorescence was detected at the end of each 60 1C phase. The transcript of IGFBP7 was normalized to the transcript levels of the housekeeping gene b-actin.
Western blot HBEC were lysed in radioimmuno precipitation assay buffer (1% IGEPAL, 0.5% deoxycholic acid, 0.1% SDS, protease inhibitor capsule (Sigma)) and CM were collected. The cell lysates were centrifuged at 20 000 g for 10 min at 4 1C and protein content in the supernatant was measured using BCA protein assay (Pierce, Rockford, IL, USA). For detection of Smad proteins, nuclear extracts were isolated using a Nuclear Extraction Kit (Panomics, Redwood City, CA, USA) as described by manufacturer's protocol. Total protein per sample (10-20 mg) or equal volumes of CM were subjected to 12% SDS-PAGE; proteins were then transferred to Immobilon membrane (Millipore, Bedford, MA, USA). The membrane was blocked with 5% skim milk in TBST (20 mmol/ l Tris-HCl (pH 8.0), 137 mmol/l NaCl and 0.1% Tween 20) for 1 h at room temperature (RT) and incubated with the primary antibodies overnight at 4 1C. After washing with TBST, blots were probed with HRP-conjugated secondary antibodies (anti-mouse immunoglobulin G (IgG), antirabbit IgG or anti-goat IgG) (Sigma) for 1 h at RT. Immunoblots were visualized using Amersham Biosciences enhanced chemiluminescence detection system (Piscataway, NJ, USA).
Capillary-like tube formation
In vitro angiogenesis was assessed by endothelial tube formation in growth factor reduced Matrigel (BD Biosciences). To allow the Matrigel solution to polymerize, 24-well plates were coated with 300 ml of diluted Matrigel solution and incubated at 37 1C for at least 1 h. HBEC (40 000 cells) were harvested and suspended in one of the following: 500 ml DMEM alone, DMEM supplemented with 10, 50 or 200 nM of recombinant IGFBP7, serum-free U87MG-CM alone or supplemented with 10 mM of SB431542. HBEC were then plated on top of the solidified Matrigel solution and maintained at 37 1C. Endothelial tube formation was digitally photographed under a phase contrast Olympus 1 Â 50 microscope (Olympus U-CMT) at Â 4 magnification, 24 h after treatment. Captured images were analysed using Northern Eclipse v.5.0 software. Images were thresholded, converted to binary images and skeletonized. The total length of the CLT networks and the number of nodes (branching points) formed by HBEC were quantified. Experiments were performed with at least three different HBEC isolations. Each set of forward and reverse primers was designed from NCBI published sequences using the Primer Express Software v.2.0.
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Statistical analysis
Results are expressed as mean ± s.e.m. The unpaired t-test was used for single comparisons of groups with equal variance and normal distribution. Analysis of variance (ANOVA) followed by Newman-Keuls posttest was used to compare multiple data to each group.
